Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow (FCF).

## 1177 Free Cash Flow Analysis

Free cash flow, a measure commonly used by analysts to assess a company's profitability, represents the cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

The Free Cash Flow is calculated using a number of methods including using Operating Cash Flow. Following is the formula to calculate Free Cash Flow based on Operating Cash Flow.

`Free Cash Flow = Operating Cash Flow - Capital Expenditures`

Using above formula to calculate Free Cash Flow for Sino Biopharmaceutical Limited (1177), the free cash flow value is 3.652163B.

All amounts in CNY

Operating Cash
5.37B
Capital Expenditure
-1.71B
Free Cash Flow
3.652163B

Sino Biopharmaceutical Limited has a positive free cash flow as per the latest annual Cash flow statement released by the company. Positive free cash flow is cruscial for the financial health of a company, which can be used to pay dividends, expand operations, and deleverage its balance sheet (i.e., reduce debt).

## 1177 Cash Flow Statement History

Following table shows the history of Cash Flow Statements sheet for Sino Biopharmaceutical Limited (HKEX:1177).

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Net Income14.61B2.77B2.76B9.05B
Depreciation922.74M1.64B1.4B1.16B
Change To Netincome-9.96B568.8M1.36B-5.42B
Change To Account Receivables-1.31B-198.79M196.31M-436.21M
Change To Liabilities-191.59M334.05M-143.2M870.48M
Change To Inventory-57.48M-221.45M-449.44M-102.16M
Change To Operating Activities1.22B347.52M113.52M-88.81M
Total Cash From Operating Activities5.37B5.33B5.32B5.09B
Capital Expenditures-1.71B-1.42B-1.45B-1.55B
Investments-4.39B-6.54B-2.45B-668.25M
Other Cashflows From Investing Activities4.41B383.13M343.89M510.46M
Total Cashflows From Investing Activities-2.52B-7.85B-3.82B-616.1M
Dividends Paid-938.49M-1.19B-819.69M-710.33M
Net Borrowings-1.5B5.34B5.17B304.67M
Other Cashflows From Financing Activities-452.37M-1.72B-1.51B-1.17B
Total Cash From Financing Activities-3.23B2.23B2.8B-2.18B
Effect Of Exchange Rate-649.71M280.01M95.05M242.47M
Change In Cash-1.02B-7.02M4.4B2.54B
Repurchase Of Stock-332.93M-195.37M-32.05M-604.42M